127 related articles for article (PubMed ID: 35679751)
1. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer.
Shen X; Chen Y; Liu M; Shi J; Tang Y; Yang X; Xu D; Yao H; Lu P; Sun Y; Xue J; Niu N
Biochem Biophys Res Commun; 2022 Jul; 615():9-16. PubMed ID: 35679751
[TBL] [Abstract][Full Text] [Related]
2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
3. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.
Niu N; Lu P; Yang Y; He R; Zhang L; Shi J; Wu J; Yang M; Zhang ZG; Wang LW; Gao WQ; Habtezion A; Xiao GG; Sun Y; Li L; Xue J
Gut; 2020 Apr; 69(4):715-726. PubMed ID: 31300513
[TBL] [Abstract][Full Text] [Related]
4. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer.
Nie H; Huang PQ; Jiang SH; Yang Q; Hu LP; Yang XM; Li J; Wang YH; Li Q; Zhang YF; Zhu L; Zhang YL; Yu Y; Xiao GG; Sun YW; Ji J; Zhang ZG
Theranostics; 2021; 11(8):3898-3915. PubMed ID: 33664869
[TBL] [Abstract][Full Text] [Related]
5. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
7. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.
Zhang X; Xu J; Yan R; Zhang Y; Hu Z; Fu H; You Q; Cai Q; Yang D
Aging (Albany NY); 2020 Apr; 12(8):6808-6822. PubMed ID: 32291380
[TBL] [Abstract][Full Text] [Related]
8. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
9. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
10. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.
Shukla SK; Purohit V; Mehla K; Gunda V; Chaika NV; Vernucci E; King RJ; Abrego J; Goode GD; Dasgupta A; Illies AL; Gebregiworgis T; Dai B; Augustine JJ; Murthy D; Attri KS; Mashadova O; Grandgenett PM; Powers R; Ly QP; Lazenby AJ; Grem JL; Yu F; Matés JM; Asara JM; Kim JW; Hankins JH; Weekes C; Hollingsworth MA; Serkova NJ; Sasson AR; Fleming JB; Oliveto JM; Lyssiotis CA; Cantley LC; Berim L; Singh PK
Cancer Cell; 2017 Jul; 32(1):71-87.e7. PubMed ID: 28697344
[TBL] [Abstract][Full Text] [Related]
11. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
13. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
14. S100A11 activates the pentose phosphate pathway to induce malignant biological behaviour of pancreatic ductal adenocarcinoma.
Zeng X; Guo H; Liu Z; Qin Z; Cong Y; Ren N; Zhang Y; Zhang N
Cell Death Dis; 2022 Jun; 13(6):568. PubMed ID: 35752610
[TBL] [Abstract][Full Text] [Related]
15. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
16. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
17. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
18. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
[TBL] [Abstract][Full Text] [Related]
19. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
[TBL] [Abstract][Full Text] [Related]
20. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
